Arovella Advances CAR-iNKT Trials with $14.4 Million Cash Backing

Clinical Trial Launch Imminent for Lead CAR-iNKT Therapy

Arovella Therapeutics (ASX:ALA) is on the cusp of a major clinical milestone with ethics approval secured to commence its phase 1 trial of ALA-101, an allogeneic CAR-iNKT cell therapy targeting relapsed or refractory CD19-positive blood cancers. The trial, set to start dosing patients in September 2026 across up to seven sites in Australia and New Zealand, will evaluate safety, tolerability, and preliminary efficacy using an adaptive Bayesian dose escalation design. Manufacturing of the first clinical batch of ALA-101 is complete and undergoing release testing, marking a critical step towards first-in-human data that could validate the company’s novel cell therapy platform.

Solid Tumour Program Gains Momentum with Armoured CAR-iNKT Cells

Beyond blood cancers, Arovella is advancing its solid tumour candidate ALA-105, which targets CLDN18.2, a validated antigen expressed in up to 70% of gastric and 60% of pancreatic cancers. Preclinical data showcased at international conferences demonstrated that ALA-105’s armoured CAR-iNKT cells, fortified with IL-12-TM cytokine technology, maintain potent and durable tumour-killing activity over multiple tumour challenges in vitro. The company has established relevant in vivo mouse models and plans to initiate efficacy studies shortly, potentially broadening the clinical scope of its CAR-iNKT platform.

Refined Autoimmune Strategy Leveraging B Cell Depletion

Arovella is sharpening its focus on autoimmune diseases driven by aberrant B cells, such as lupus and myasthenia gravis. The phase 1 trial of ALA-101 will include monitoring of B cell depletion, a mechanism that could inform future clinical trials targeting autoimmune indications. This dual oncology-autoimmune approach hinges on the therapy’s ability to selectively eliminate CD19-positive B cells, potentially offering a new avenue for patients refractory to conventional immunosuppression.

Leadership Overhaul and Board Refresh

The quarter saw significant governance changes with the appointment of three new Non-Executive Directors, including Chairman David Williams, following a shareholder-driven board reshuffle. Dr Michael Baker resigned as CEO and Managing Director, succeeded by acting CEO Dr Nicole Van Der Weerden, a seasoned biotech executive with a strong operational background. The company also bolstered its clinical advisory board with Professor Cameron Turtle, a recognized expert in cellular immunotherapy, to guide its clinical development efforts.

Financial Position Supports Upcoming Milestones

Arovella closed the quarter with $14.4 million in cash and equivalents, a runway estimated to cover over six quarters at current operating burn rates. Research and development plus staff costs accounted for 89% of operating outflows, reflecting the company’s commitment to progressing its pipeline. Upcoming catalysts include the initiation of the ALA-101 trial, release testing completion, and in vivo efficacy data from the solid tumour program. Investor engagement has also been ramped up, with recent appearances on Sky News and features in the Australian Financial Review.